Bluejay Diagnostics, Inc. Debt Conversion, Converted Instrument, Amount
Bluejay Diagnostics, Inc. (BJDX) reported Debt Conversion, Converted Instrument, Amount of $8.51 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-03-20
- Bluejay Diagnostics, Inc. debt conversion, converted instrument, amount for fiscal 2021 was $8.51M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2021-12-31 | $8.51M 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |